Pooled CRISPR-Based Genetic Screens in Mammalian Cells
September 4th, 2019
23.7K views
CRISPR-Cas9 technology provides an efficient method to precisely edit the mammalian genome in any cell type and represents a novel means to perform genome-wide genetic screens. A detailed protocol discussing the steps required for the successful performance of pooled genome-wide CRISPR-Cas9 screens is provided here.
Overview
This article presents a comprehensive protocol for performing pooled genome-wide CRISPR-Cas9 based screens in mammalian cells. The method enables systematic, high-throughput interrogation of gene function by leveraging libraries of single guide RNAs (sgRNAs) to induce targeted genetic perturbations across the genome. The protocol covers practical aspects from library preparation to data analysis, facilitating functional genomics studies and the identification of context-specific essential genes.
Key Study Components
Area of Science
- Functional genomics
- Genome editing
- Molecular biology
- Cancer research
Background
- CRISPR-Cas9 technology allows precise genome editing in various organisms.
- Pooled sgRNA libraries enable genome-wide genetic screens in a single experiment.
- These screens are used to identify essential genes, map genetic interactions, and profile drug mechanisms.
- Genome-wide screens require handling large cell numbers and complex data analysis.
Purpose of Study
- To provide a detailed, practical protocol for conducting pooled CRISPR-Cas9 screens in mammalian cells.
- To highlight key considerations for successful screen execution, including cell line characterization and library coverage.
- To demonstrate methods for maintaining guide RNA representation and minimizing technical artifacts.
Methods Used
- Transformation of CRISPR sgRNA plasmids into electrocompetent cells and plasmid purification.
- Lipid-based transfection of 293T cells for lentiviral packaging of sgRNA libraries.
- Lentiviral transduction of target cells at defined multiplicity of infection (MOI) to ensure library coverage.
- Selection, expansion, and passaging of infected cells with systematic sampling for genomic DNA extraction.
- PCR amplification of sgRNA regions, next-generation sequencing, and data analysis including precision-recall evaluation.
Main Results
- Efficient generation and maintenance of genome-wide sgRNA libraries in mammalian cells.
- Reliable identification of essential genes and genetic interactions through dropout and positive selection screens.
- Demonstration of methods to ensure even guide RNA distribution and minimize false positives/negatives.
- Validation of screen performance using precision-recall curves and Bayes factor analysis.
Conclusions
- Pooled CRISPR-Cas9 screens are accessible, efficient, and powerful tools for functional genomics.
- Careful experimental design and execution are critical for robust results.
- These screens enable broad application in biological research and disease modeling.
Frequently Asked Questions
What is the main advantage of pooled CRISPR-Cas9 screens?
They allow high-throughput, unbiased interrogation of gene function across the entire genome in a single experiment, enabling systematic discovery of essential genes and genetic interactions.
How is guide RNA library representation maintained during the screen?
By carefully controlling cell numbers, infection conditions, and passaging, and by monitoring guide RNA distribution at each step to minimize random effects and technical biases.
What are key considerations before starting a CRISPR screen?
Cell line characterization (purity, doubling time, transduction efficiency, antibiotic sensitivity) and ensuring sufficient library coverage are essential for reliable results.
How are screen results validated?
Primary hits from the screen should be confirmed with follow-up experiments, such as individual gene knockouts and phenotypic assays, to verify their biological relevance.
What methods are used to analyze screen performance?
Precision-recall analysis and Bayes factor calculations are used to assess the recovery of essential genes and the confidence in gene knockout effects.
Can this protocol be adapted for other species?
Yes, while the described libraries target human cells, similar approaches can be used for other organisms, such as mouse, with appropriate sgRNA libraries.
What are common applications of genome-wide CRISPR screens?
Applications include identifying essential genes in cancer, mapping genetic interactions, and profiling drug mechanisms of action.
Executive Industry Relevance
Pooled CRISPR-based genetic screens in mammalian cells enable systematic, high-throughput interrogation of gene function, supporting early discovery and target validation in biopharma pipelines. This approach delivers predictive confidence for essential gene identification and mechanistic de-risking, directly impacting portfolio triage and prioritization. The scalability and unbiased nature of these screens position them as foundational tools for functional genomics and disease-relevant target discovery.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables genome-wide interrogation of gene function to clarify biological pathways.
- Supports functional target validation by identifying essential genes in disease models.
- Facilitates mechanistic de-risking through unbiased, systematic perturbation analysis.
- Provides predictive confidence for advancing targets into downstream workflows.
Screening & Assay Development
- Prepares validated cell systems for robust, reproducible screening campaigns.
- Standardizes assay conditions to ensure quantitative, comparable outputs across replicates.
- Enables scalable screening of thousands of genetic perturbations in a single experiment.
- Supports reliable compound evaluation by mapping genetic interactions and drug mechanisms.
Translational & Preclinical Research
- Aligns genetic findings with disease-relevant models for translational continuity.
- Enables identification of context-specific essential genes in cancer and other diseases.
- Supports risk-adjusted advancement decisions by linking functional genomics to preclinical endpoints.
- Provides a platform for biomarker discovery and validation when supported by screen outputs.
Pipeline & Workflow Integration
Pooled CRISPR screens integrate at the early discovery and target validation stages, bridging to lead identification and preclinical research when essential gene hits are confirmed and prioritized.
- Discovery Biology: Facilitates hypothesis testing and pathway clarification through genome-scale perturbation.
- Screening: Delivers reproducible, quantitative readouts for robust comparison of genetic and pharmacological conditions.
- Analytics: Provides precision-recall and Bayes factor outputs to support data-driven decision making.
- Translational Research: Connects genetic screen results to disease models for preclinical validation.
- Enterprise Reuse: Establishes a reusable screening platform adaptable to diverse cell types and disease contexts.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in target selection.
- Operational Value: Standardizes workflows for scalability and reproducibility across large cell populations.
- Strategic Value: Improves go/no-go decisions and capital efficiency by focusing on validated targets.
- Portfolio Impact: Enables risk-adjusted prioritization and advancement of high-confidence targets.
Implementation Considerations
- Requires expertise in genome editing, cell culture, and high-throughput screening.
- Demands robust instrumentation for cell handling, next-generation sequencing, and data analysis.
- Necessitates cross-team standardization to maintain guide RNA representation and minimize technical artifacts.
- Must adapt protocols for different cell lines and species as needed.
- Careful management of library coverage and data quality is critical for reliable results.
Biopharma FAQs
Why does null hypothesis testing matter for CRISPR screen target validation?
Null hypothesis testing in pooled CRISPR screens enables objective assessment of whether gene knockouts produce significant phenotypic changes, supporting rigorous target validation and reducing false positives in early discovery.
How does independent variable isolation fit pooled CRISPR screen workflows?
By systematically perturbing individual genes with unique guide RNAs, pooled CRISPR screens isolate the effects of each genetic variable, allowing clear attribution of observed phenotypes to specific gene disruptions.
What do quantitative dependent variable measurements enable in CRISPR screens?
Quantitative readouts, such as guide RNA abundance from sequencing, enable precise comparison of gene effects, facilitate robust statistical analysis, and support confident identification of essential genes and genetic interactions.
Why are replication requirements critical for cross-functional CRISPR screen collaboration?
Replicating pooled screens ensures reproducibility and reliability of results, enabling cross-team validation and increasing confidence in hits prioritized for downstream functional studies or therapeutic development.
What statistical analysis capabilities are required before implementing pooled CRISPR screens?
Capabilities such as precision-recall analysis and Bayes factor calculation are essential to evaluate screen performance, control false discovery rates, and provide actionable confidence metrics for gene prioritization.
Chapters in this video
0:04
Title
1:36
Pooled CRISPR sgRNA Lentiviral Library Plasmid Amplification
2:24
Large-scale CRISPR sgRNA Library Lentivirus Production
3:47
Primary Screen Infection, Selection, and Cell Passaging
5:41
CRISPR Sample Preparation and Sequencing
6:43
Results: Genome-scale CRISPR Screening
7:54
Conclusion
